1-Piperideine is a heterocyclic compound with a six-membered ring containing one nitrogen atom. It is an important intermediate in the synthesis of various pharmaceuticals and other organic compounds. The compound is also a substrate for a number of enzymes, including monoamine oxidase, which is responsible for the breakdown of neurotransmitters such as dopamine, serotonin, and norepinephrine. 1-Piperideine has been studied for its potential therapeutic applications, particularly in the treatment of Parkinson's disease, Alzheimer's disease, and depression. '
1-piperideine: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 68161 |
| CHEBI ID | 47858 |
| MeSH ID | M0127687 |
| Synonym |
|---|
| delta1-piperideine |
| .delta.1-piperideine |
| inchi=1/c5h9n/c1-2-4-6-5-3-1/h4h,1-3,5h |
| pyridine, 2,3,4,5-tetrahydro- |
| 2,3,4,5-tetrahydropyridine |
| C06181 |
| piperideine |
| 1-piperideine |
| delta(1)-piperideine |
| 505-18-0 |
| CHEBI:47858 |
| 2,3,4,5,-tetrahydropyridine |
| dehydropiperidine |
| DTXSID20198514 |
| Q27104595 |
| 10-acetyl-phenoxazine-3,7-dioldiacetate |
| piperideine, trimere |
| Class | Description |
|---|---|
| piperideine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| L-lysine degradation X | 2 | 19 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.39) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||